Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Provided herein is the use of heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases. Specifically, disclosed is the use of compounds of formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug thereof; and application thereof. Definition of each group in the formula can be found in the specification for details.

##STR00001##

A composition for treating skin wounds of an individual is disclosed. The composition is an extract that contains Zinc Gluconate, Lysine, Taurine, Potassium Gluconate, Carboxy Methyl Cellulose, Glycerin, Allantoin, water, Hydrogen chloride (HCl), Lidocaine, Niacin, Valine, L-Isoleucine, Proline, L-Arginine, Threonine, Glutamine, Histidine, Serine, Asparagine, Tyrosine, Cysteine, and pentapeptide for example, Enkephalin. The composition could be applied to the affected skin for effectively treating skin wounds, reducing expression lines, and relaxing muscle contractions, thereby reducing skin wrinkles, and smoothening skin. The composition is provided in at least any one or more forms include a gel, a spray, liquid, lotion, and a cream. The composition maintains a pH balance ranges from about 6.5 to 7.5.

A composition for treating skin wounds of an individual is disclosed. The composition is an extract that contains Zinc Gluconate, Lysine, Taurine, Potassium Gluconate, Carboxy Methyl Cellulose, Glycerin, Allantoin, water, Hydrogen chloride (HCl), Lidocaine, Niacin, Valine, L-Isoleucine, Proline, L-Arginine, Threonine, Glutamine, Histidine, Serine, Asparagine, Tyrosine, Cysteine, and pentapeptide for example, Enkephalin. The composition could be applied to the affected skin for effectively treating skin wounds, reducing expression lines, and relaxing muscle contractions, thereby reducing skin wrinkles, and smoothening skin. The composition is provided in at least any one or more forms include a gel, a spray, liquid, lotion, and a cream. The composition maintains a pH balance ranges from about 6.5 to 7.5.

A composition for treating skin wounds of an individual is disclosed. The composition is an extract that contains Zinc Gluconate, Lysine, Taurine, Potassium Gluconate, Carboxy Methyl Cellulose, Glycerin, Allantoin, water, Hydrogen chloride (HCl), Lidocaine, Niacin, Valine, L-Isoleucine, Proline, L-Arginine, Threonine, Glutamine, Histidine, Serine, Asparagine, Tyrosine, Cysteine, and pentapeptide for example, Enkephalin. The composition could be applied to the affected skin for effectively treating skin wounds, reducing expression lines, and relaxing muscle contractions, thereby reducing skin wrinkles, and smoothening skin. The composition is provided in at least any one or more forms include a gel, a spray, liquid, lotion, and a cream. The composition maintains a pH balance ranges from about 6.5 to 7.5.

Multiparticulate compositions including an active agent and a gelling agent are disclosed. The multiparticulate compositions are prepared by an aqueous-based spray and congeal process.

A method of treating cardiovascular disorders and diseases in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to promote S-nitrosylation of proteins in the subject, wherein the ADH inhibitor and/or SNO-CoAR inhibitor is not an ADH3 inhibitor.

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.